Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma
Author:
Affiliation:
1. Dana-Farber Cancer Institute, Boston, Massachusetts
2. Bristol-Myers Squibb, Lawrenceville, New Jersey
Publisher
American Medical Association (AMA)
Subject
Oncology,Cancer Research
Link
https://jamanetwork.com/journals/jamaoncology/articlepdf/2749253/jamaoncology_braun_2019_ld_190018.pdf
Reference4 articles.
1. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.;Motzer;N Engl J Med,2015
2. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.;Miao;Science,2018
3. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration.;Thorvaldsdóttir;Brief Bioinform,2013
4. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.;McDermott;Nat Med,2018
Cited by 179 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Personalized treatment using predictive biomarkers in solid organ malignancies: A review;Tumori Journal;2024-08-02
2. Organoids: new frontiers in tumor immune microenvironment research;Frontiers in Immunology;2024-07-29
3. Multifunctional Biomimetic Nanocarriers for Dual‐Targeted Immuno‐Gene Therapy Against Hepatocellular Carcinoma;Advanced Science;2024-07-08
4. Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors;Clinical Genitourinary Cancer;2024-07
5. Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma;Journal of Clinical Investigation;2024-05-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3